Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
Integrated BioPharma reported FY26 revenue of $43.9 million, down 19.3% from $54.4 million, swinging from $2.0 million in operating income to a $2.7 million operating loss. The fiscal fourth quarter was worse: revenue fell 31% to $9.8 million, with gross profit collapsing to just $28 thousand and a net loss of $1.4 million ($0.04 per share).
Key figures
- Revenue
- 43872000
- Revenue Yoy
- -19.3%
- Q4 revenue
- 9796000
- Q4 revenue yoy
- -31.0%
- Gross profit fy
- 800000
- Top two customer concentration
- 90% of FY26 revenue (84% in FY25)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.